旺山旺水
VIGONVITA

Vigonvita Life Sciences Co., Ltd.
蘇州旺山旺水生物醫藥股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2630)

(1) POLL RESULTS OF THE POSTPONED ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026;
(2) ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION;
(3) RE-ELECTION OF DIRECTORS;
(4) APPOINTMENT OF THE CHAIRMAN OF THE SECOND SESSION OF THE BOARD;
(5) APPOINTMENT OF SENIOR MANAGEMENT;
AND
(6) APPOINTMENT OF MEMBERS OF THE COMMITTEES UNDER THE SECOND SESSION OF THE BOARD

References are made to the notice (the "**Notice**") of the annual general meeting (the "**AGM**") and the circular (the "**Circular**") of Vigonvita Life Sciences Co., Ltd. (the "**Company**") dated June 4, 2026, and the supplemental notice of the annual general meeting (the "**Supplemental Notice**") and the supplemental circular of the Company (the "**Supplemental Circular**", together with the Circular, collectively referred to as the "**Circulars**") dated June 14, 2026. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circulars. The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that the postponed annual general meeting of the Company (the "**Postponed AGM**") was held at 8th Floor, Building A, No. 108, Yuxin Road, Suzhou Industrial Park District, Suzhou, the PRC at 10:00 a.m. on Tuesday, June 30, 2026.

As at the date of the Postponed AGM, the total number of issued Shares of the Company was 167,597,800 Shares, comprising 100,920,667 Unlisted Shares and 66,677,133 H Shares. The Company did not hold any treasury Shares or repurchased Shares pending cancellation. Accordingly, the total number of Shares entitling the holders to attend the Postponed AGM and vote on the resolutions proposed at the Postponed AGM was 167,597,800 Shares, representing 100% of the total issued Shares of the Company.

ATTENDANCE AT THE POSTPONED AGM

The Board comprises 6 members, all of whom attended the Postponed AGM in person or by electronic means. The Supervisors and senior management of the Company were also present at the Postponed AGM.

The Shareholders or authorized proxies of the Shareholders attending the Postponed AGM held an aggregate of 117,503,671 Shares carrying voting rights, representing approximately 70.11% of the total issued Shares of the Company. Voting at the Postponed AGM was conducted by way of poll. The Postponed AGM was convened and held in accordance with the applicable PRC laws and regulations, the Listing Rules and the Articles of Association.

(i) No Shareholder was subject to any restriction on voting on any of the proposed resolutions at the Postponed AGM; (ii) no Shareholder was required under the Listing Rules to abstain from voting on the proposed resolutions at the Postponed AGM; (iii) there were no Shares entitling the holders to attend the Postponed AGM and abstain from voting in favour of the proposed resolutions at the Postponed AGM as required under Rule 13.40 of the Listing Rules; and (iv) no party had stated in the Circulars any intention to vote against or abstain from voting on the proposed resolutions at the Postponed AGM.

Computershare Hong Kong Investor Services Limited, the H Share Registrar of the Company, acted as the scrutineer for the vote-taking at the Postponed AGM.

POLL RESULTS OF THE POSTPONED AGM

All resolutions proposed at the Postponed AGM were voted on by poll. The poll results were as follows:

Ordinary Resolutions		**Number of Votes (Percentage of the Total Voting Shares at the Postponed AGM)**			**Passed by Shareholders**
		For	**Against**	**Abstain**	
1.	To consider and approve the 2025 annual report of the Company.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
2.	To consider and approve the work report of the Board of Directors of the Company for 2025.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
3.	To consider and approve the final accounts report of the Company for 2025.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes

Ordinary Resolutions		Number of Votes (Percentage of the Total Voting Shares at the Postponed AGM)			Passed by Shareholders
		For	Against	Abstain	
4.	To consider and approve the profit distribution plan of the Company for 2025.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
5.	To consider and approve the work report of independent non-executive Directors for 2025.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
6.	To consider and approve the remuneration package of Directors for 2026.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
7.	To consider and approve the proposed provision of guarantees for subsidiaries.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
8.	To consider and approve the proposed amendments to the Rules of Procedure for Shareholders' Meetings and the Rules of Procedure for Board Meetings.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
9.	To consider and approve the appointment of HLB Hodgson Impey Cheng Limited as the auditor of the Company and authorization of the Board to fix its remuneration.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes

Ordinary Resolutions (By way of Cumulative Voting)		Cumulative Votes (Percentage of the Valid Voting Rights at the Postponed AGM)	Passed by Shareholders
10.	To consider and approve the election of non-independent Directors of the second session of the Board:		
10.1	To elect Dr. Tian Guanghui as an executive Director of the second session of the Board of the Company;	117,503,671 (100%)	Yes
10.2	To elect Dr. Hu Tianwen as an executive Director of the second session of the Board of the Company;	117,503,671 (100%)	Yes
10.3	To elect Mr. Liu Haoxuan as a non-executive Director of the second session of the Board of the Company;	103,974,075 (88.49%)	Yes
10.4	To elect Ms. Ding Hongfei as a non-executive Director of the second session of the Board of the Company.	13,529,594 (11.51%)	No
11.	To consider and approve the election of independent non-executive Directors of the second session of the Board:		
11.1	To elect Dr. Ju Dianwen as an independent non-executive Director of the second session of the Board of the Company;	117,503,671 (100%)	Yes
11.2	To elect Ms. Cao Xinwen as an independent non-executive Director of the second session of the Board of the Company;	117,503,671 (100%)	Yes
11.3	To elect Dr. Xu Hongxi as an independent non-executive Director of the second session of the Board of the Company.	117,503,671 (100%)	Yes

Special Resolutions		Number of Votes (Percentage of the Total Voting Shares at the Postponed AGM)			Passed by Shareholders
		For	Against	Abstain	
12.	To propose the abolition of the Supervisory Committee and the amendments to the Articles of Association.	110,328,913 (93.89%)	0 (0%)	7,174,758 (6.11%)	Yes
13.	To consider and approve the general mandate to issue H Shares.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes
14.	To consider and approve the general mandate to repurchase H Shares.	117,503,671 (100%)	0 (0%)	0 (0%)	Yes

Notes:

(1) As more than one-half of the votes were cast in favour of each of the resolutions numbered 1 to 9 above, such resolutions were duly passed as ordinary resolutions of the Company.

(2) In respect of resolutions numbered 10 to 11 above, the Company adopted the cumulative voting system for voting and counting the poll results. The candidates under sub-resolutions numbered 10.1 and 10.2 and the sub-resolutions under resolution numbered 11 each received a vote count of more than one-half of the total number of Shares carrying voting rights held by the Shareholders attending the Postponed AGM before cumulation, such resolutions were duly passed and thus were elected as Directors.

As set out in the Circulars, in respect of ordinary resolutions numbered 10.3 and 10.4, the Company would conduct a competitive election by way of cumulative voting to elect one non-executive Director from two candidates. The candidate who obtained the highest number of affirmative votes among the two candidates and whose affirmative votes represented more than one-half, including one-half, of the number of Shares carrying voting rights held by the Shareholders attending the Postponed AGM would be elected as a non-executive Director of the second session of the Board. As ordinary resolution numbered 10.3 obtained more than one-half of the total votes and was the only one of ordinary resolutions numbered 10.3 and 10.4 that was passed, such resolution was duly passed.

(3) As more than two-thirds of the votes were cast in favour of each of the resolutions numbered 12 to 14 above, such resolutions were duly passed as special resolutions of the Company.

ABOLITION OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Reference is made to the Notice and the Circular in relation to, among other things, the proposed abolition of the Supervisory Committee and amendments to the Articles of Association.

The proposed abolition of the Supervisory Committee and the amendments to the Articles of Association were approved by the Shareholders by way of a special resolution at the Postponed AGM and became effective on June 30, 2026. The Company will no longer have any Supervisors or a Supervisory Committee, and the Rules of Procedure of the Supervisory Committee and other rules and systems relating to the Supervisory Committee will be repealed accordingly. Each of the Supervisors has confirmed that he or she had no disagreement with the Board or the Supervisory Committee, and that there are no other matters in relation to his or her departure that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Company would like to express its sincere gratitude to all Supervisors for their contributions to the Company during their respective terms of office.

The full text of the amended Articles of Association will be published on the websites of the Stock Exchange and the Company, respectively.

RE-ELECTION OF DIRECTORS

Following the passing of ordinary resolutions numbered 10 to 11 by the Shareholders at the Postponed AGM, the Board is pleased to announce that:

(1) Dr. Tian Guanghui and Dr. Hu Tianwen were re-elected as executive Directors of the second session of the Board;

(2) Mr. Liu Haoxuan was re-elected as a non-executive Director of the second session of the Board; and

(3) Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi were re-elected as independent non-executive Directors of the second session of the Board.

The terms of office of the members of the second session of the Board shall be three years commencing from the date of consideration and approval of their election at the Postponed AGM, and shall take effect from June 30, 2026. Their biographical details and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out in the Circulars. As at the date of this announcement, there has been no change in such information.

Each of the Directors of the second session of the Board will enter into a service contract or letter of appointment with the Company, and they will receive remuneration in accordance with the Remuneration Package of Directors for 2026 approved at the Postponed AGM, and the details of their respective remuneration will also be disclosed in the Company's annual report published each year.

APPOINTMENT OF THE CHAIRMAN OF THE SECOND SESSION OF THE BOARD

The Board further announces that, at the first meeting of the second session of the Board held immediately following the Postponed AGM, Dr. Tian Guanghui was appointed as the chairman of the second session of the Board for a term of three years commencing from June 30, 2026 until the expiry of the term of the second session of the Board.

APPOINTMENT OF SENIOR MANAGEMENT

The Board further announces that, upon consideration and approval by the Board on June 30, 2026, Dr. Tian Guanghui was appointed as the general manager of the Company, Dr. Hu Tianwen and Dr. Wang Zhiqiang were appointed as deputy general managers of the Company, Ms. Guo Ting was appointed as the secretary to the Board of the Company, and Ms. Yao Zheng was appointed as the person in charge of finance of the Company. The terms of office of the above senior management members shall be three years commencing from June 30, 2026 until the expiry of the term of the second session of the Board. For the biographical details of Dr. Wang Zhiqiang, Ms. Guo Ting and Ms. Yao Zheng, please refer to the 2025 annual report of the Company.

APPOINTMENT OF MEMBERS OF THE COMMITTEES UNDER THE SECOND SESSION OF THE BOARD

The Board further announces that it has resolved to appoint the members of the committees under the second session of the Board, with effect from June 30, 2026, the composition of the Audit Committee, the Nomination Committee and the Remuneration and Appraisal Committee of the Board is as follows:

(1) Audit Committee: Ms. Cao Xinwen (chairperson, who possesses the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules), Dr. Xu Hongxi and Dr. Ju Dianwen;

(2) Nomination Committee: Dr. Tian Guanghui (chairperson), Dr. Xu Hongxi and Ms. Cao Xinwen; and

(3) Remuneration and Appraisal Committee: Dr. Xu Hongxi (chairperson), Dr. Hu Tianwen and Dr. Ju Dianwen.

Each of the members of the Board committees has been appointed for a term concurrent with the term of the second session of the Board.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager

Hong Kong, June 30, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.